BR0206433A - Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto - Google Patents

Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto

Info

Publication number
BR0206433A
BR0206433A BR0206433-2A BRPI0206433A BR0206433A BR 0206433 A BR0206433 A BR 0206433A BR PI0206433 A BRPI0206433 A BR PI0206433A BR 0206433 A BR0206433 A BR 0206433A
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
compounds
useful
Prior art date
Application number
BR0206433-2A
Other languages
English (en)
Inventor
Terrence D Butters
Raymond A Dwek
George Fleet
Michael Glen Orchard
Frances Mary Platt
Original Assignee
Oxford Glycosciences
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences, Univ Oxford filed Critical Oxford Glycosciences
Publication of BR0206433A publication Critical patent/BR0206433A/pt
Publication of BRPI0206433B1 publication Critical patent/BRPI0206433B1/pt
Publication of BRPI0206433B8 publication Critical patent/BRPI0206433B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, E, USO DE UM COMPOSTO". Compostos de fórmula (I): em que R representa vários grupos substituintes, são úteis como inibidores de glucosilceramida sintase.
BR0206433-2 2001-01-12 2002-01-11 composto, composição farmacêutica, e, uso de um composto BRPI0206433B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0100889.5 2001-01-12
GBGB0100889.5A GB0100889D0 (en) 2001-01-12 2001-01-12 Compounds
PCT/GB2002/000106 WO2002055498A1 (en) 2001-01-12 2002-01-11 Pharmaceutically active piperidine derivatives

Publications (3)

Publication Number Publication Date
BR0206433A true BR0206433A (pt) 2003-12-30
BRPI0206433B1 BRPI0206433B1 (pt) 2020-01-07
BRPI0206433B8 BRPI0206433B8 (pt) 2021-05-25

Family

ID=9906757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206433-2 BRPI0206433B8 (pt) 2001-01-12 2002-01-11 composto, composição farmacêutica, e, uso de um composto

Country Status (19)

Country Link
US (3) US20040097551A1 (pt)
EP (1) EP1362031B1 (pt)
JP (1) JP4313572B2 (pt)
KR (1) KR100879651B1 (pt)
CN (1) CN1267420C (pt)
AT (1) ATE389635T1 (pt)
AU (1) AU2002219363B2 (pt)
BR (1) BRPI0206433B8 (pt)
CA (1) CA2433675C (pt)
DE (1) DE60225671T2 (pt)
ES (1) ES2304439T3 (pt)
GB (1) GB0100889D0 (pt)
HU (1) HU229428B1 (pt)
IL (1) IL156873A0 (pt)
MX (1) MXPA03006185A (pt)
PT (1) PT1362031E (pt)
RU (1) RU2279425C2 (pt)
WO (1) WO2002055498A1 (pt)
ZA (1) ZA200305118B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1524976B1 (en) * 2002-03-13 2006-09-13 Unither Pharmaceuticals, Inc. A non-hormonal approach to male contraception
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
CA2492410C (en) 2002-07-17 2011-09-13 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
GB0313677D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
DE602004030604D1 (de) * 2003-10-29 2011-01-27 Genzyme Corp N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US20060025449A1 (en) * 2004-03-25 2006-02-02 United Therapeutics Use of N-substituted imino sugars for appetite suppression
EP1797898A4 (en) * 2004-09-08 2009-09-09 Takeda Pharmaceutical MEDICAMENT FOR THE PREVENTION / TREATMENT OF ARTERIOSCLEROSIS
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
EP2023927B1 (en) * 2006-05-24 2015-02-25 United Therapeutics Corporation Deoxynojirimycin and d-arabinitol analogs and methods of using
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
EP2594563B1 (en) 2007-05-31 2018-07-18 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
EP2209473B1 (en) * 2007-10-05 2017-11-22 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
EP2889043B1 (en) 2008-12-16 2019-04-10 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
CA2753195C (en) 2009-02-23 2015-06-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
KR20170117614A (ko) * 2009-02-24 2017-10-23 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법
EP2440205B1 (en) 2009-06-12 2014-08-27 United Therapeutics Corporation Iminosugars for use in the treatment of bunyaviral and togaviral diseases
US20110065753A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating poxviral infections
US20110065752A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating orthomyxoviral infections
EP2473046B1 (en) * 2009-09-04 2014-10-22 United Therapeutics Corporation Iminosugars for their use in the treatment of filoviral diseases
US20110136868A1 (en) * 2009-12-07 2011-06-09 University Of Oxford Agents for inhibiting osteoclastogenesis and/or osteoclast activation
ES2371398B1 (es) * 2010-06-04 2013-05-20 Bioglane, S.L.N.E. Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales.
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
EP2785335B8 (en) 2011-11-29 2017-08-02 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of darier disease
EP2968300A4 (en) * 2013-03-15 2016-09-28 Unither Virology Llc ANTIBACTERIAL COMPOUNDS
JP2016517887A (ja) * 2013-05-02 2016-06-20 ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード イミノ糖を使用した糖脂質阻害
TWI770184B (zh) 2017-06-01 2022-07-11 瑞士商愛杜西亞製藥有限公司 N-丁基脫氧半乳糖野尻黴素(N-butyldeoxygalactonojirimycin)之結晶型
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP2022531933A (ja) * 2019-05-10 2022-07-12 アレクトス セラピューティックス インコーポレイテッド 非リソソームグルコシルセラミダーゼ阻害剤及びその使用
AU2021269232A1 (en) * 2020-05-07 2022-12-08 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
CR20220600A (es) * 2020-05-07 2023-04-11 Alectos Therapeutics Inc Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
JPH02306962A (ja) 1989-05-19 1990-12-20 Meiji Seika Kaisha Ltd 新規ｎ―置換―１―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤
JPH0324057A (ja) 1989-06-22 1991-02-01 Tosoh Corp ポリヒドロキシピペリジン類及びその製造法
KR920703056A (ko) 1989-09-07 1992-12-17 아만 히데아키 항 바이러스제
EP0536402A4 (en) 1990-06-29 1993-05-12 Nippon Shinyaku Company, Limited Piperidine derivative
US5276120A (en) * 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
US5916759A (en) 1993-05-05 1999-06-29 Boehringer Mannheim Gmbh Cholesterol oxidase from Brevibacterium sterolicum
US6291657B1 (en) * 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
JP4564108B2 (ja) * 1996-07-15 2010-10-20 ジェンザイム コーポレーション デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途
EP0983239A1 (en) * 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
AU8286998A (en) * 1997-07-03 1999-01-25 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Genes for niemann-pick type c disease
CA2309321A1 (en) * 1997-11-10 1999-05-20 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
WO2000056334A1 (en) 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
ATE234626T1 (de) * 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
AU1840101A (en) * 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
EP1524976B1 (en) * 2002-03-13 2006-09-13 Unither Pharmaceuticals, Inc. A non-hormonal approach to male contraception
JP4575156B2 (ja) 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
CA2492410C (en) * 2002-07-17 2011-09-13 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds

Also Published As

Publication number Publication date
RU2279425C2 (ru) 2006-07-10
CN1496351A (zh) 2004-05-12
HU229428B1 (en) 2013-12-30
ZA200305118B (en) 2004-10-01
BRPI0206433B1 (pt) 2020-01-07
RU2003124756A (ru) 2005-01-10
PT1362031E (pt) 2008-06-12
DE60225671T2 (de) 2009-04-16
BRPI0206433B8 (pt) 2021-05-25
US20040097551A1 (en) 2004-05-20
IL156873A0 (en) 2004-02-08
CA2433675C (en) 2011-03-22
KR100879651B1 (ko) 2009-01-20
HUP0303891A2 (hu) 2004-03-29
EP1362031A1 (en) 2003-11-19
HUP0303891A3 (en) 2010-01-28
DE60225671D1 (de) 2008-04-30
JP2004517869A (ja) 2004-06-17
CA2433675A1 (en) 2002-07-18
MXPA03006185A (es) 2004-12-03
US20060074107A1 (en) 2006-04-06
GB0100889D0 (en) 2001-02-21
CN1267420C (zh) 2006-08-02
EP1362031B1 (en) 2008-03-19
US20140303208A1 (en) 2014-10-09
KR20030081383A (ko) 2003-10-17
JP4313572B2 (ja) 2009-08-12
US9199935B2 (en) 2015-12-01
US8729099B2 (en) 2014-05-20
AU2002219363B2 (en) 2007-11-01
WO2002055498A1 (en) 2002-07-18
ES2304439T3 (es) 2008-10-16
ATE389635T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
BR0314113A (pt) Derivados de amino propanol
DK0968206T3 (da) N-heterocykliske derivater som NOS-inhibitorer
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
DK0931788T3 (da) Metalloproteasehæmmere
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
NO20054787D0 (no) Indenderivater som farmasotiske midler
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
DK1268471T3 (da) N-heterocykliske derivater som NOS-inhibitorer
BRPI0512986A (pt) novos derivados de hidantoìna
BR0310077A (pt) Novos compostos e sua utilização
BRPI0517033A (pt) novos derivados de hidantoìna como inibidores de metaloproteinase
BRPI0411308A8 (pt) Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
UY28528A1 (es) Nuevos compuestos
SE0403085D0 (sv) Novel componds
BRPI0108990B8 (pt) processo para preparação de derivados de pirimidona com atividade antifungos
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
BR9911250A (pt) Processo para preparação de compostos
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
BR0113259A (pt) Processo para a preparação de um composto, composto e processo para a preparação de compostos
BR0308601A (pt) inibidores de carboxipeptidase b de plasma
BR0009453A (pt) Processo para a preparação de um composto
BRPI0417263A (pt) imidazopiridinas para uso como inibidores de secreção gástrica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER

Free format text: TRANSFERIDO DE: OXFORD GLYCOSCIENCES (UK) LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870180063890 DE 24/07/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO ?ACTELION PHARMACEUTICALS LIMITED? E O NOME DA EMPRESA CEDENTE ?ACTELION PHARMACEUTICALS LTD?.

Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITH OF OXFORD (GB) ; ACTELION PHARMACEUTICALS LIMITED (CH)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870180063890 DE 24/07/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO ?ACTELION PHARMACEUTICALS LIMITED? E O NOME DA EMPRESA CEDENTE ?ACTELION PHARMACEUTICALS LTD?.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER

Free format text: ANULADA A PUBLICACAO CODIGO 25.3 NA RPI NO 2487 DE 04/09/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/01/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/01/2022